Contents
24 April 2019
Vol 11, Issue 489
Vol 11, Issue 489
Editorial
- A decade of Science Translational Medicine
Science Translational Medicine’s co-Chief Scientific Advisors discuss challenges and opportunities for the next decade of translational research.
Research Articles
- A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity
VIB4920, a nonantibody scaffold protein, blocks CD40L and reduces autoantibodies and disease activity in patients with rheumatoid arthritis.
- A BMP/activin A chimera is superior to native BMPs and induces bone repair in nonhuman primates when delivered in a composite matrix
BV-265, a BMP-2/BMP-6/activin A chimera, delivered in a composite matrix generates bone repair in nonhuman primates at lower concentrations than BMP-2.
- Diagnosis of genetic diseases in seriously ill children by rapid whole-genome sequencing and automated phenotyping and interpretation
Automated phenotyping and interpretation of rapid whole-genome sequencing improve time to diagnosis of genetic diseases in hospitalized children.
- The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans
Propionate activates the insulin counter-regulatory hormonal response in mice, resulting in insulin resistance and weight gain.
- Chronic hypoxia–induced Cirbp hypermethylation attenuates hypothermic cardioprotection via down-regulation of ubiquinone biosynthesis
Chronic hypoxia–induced hypermethylation attenuates hypothermic cardioprotective effects of Cirbp and ubiquinone biosynthesis in rats and patients.
Editors' Choice
- A vaccine to kiss EBV goodbye
A nanoparticle Epstein-Barr virus glycoprotein gH/gL vaccine elicits antibodies that mediate cell type–independent protection from infection.
- Continuously capturing circulating cancer cells
A wearable apheresis device allows for continuous and specific capture of circulating tumor cells.
- Transcriptional adaptation: Another reason why your disease model fails you
Up-regulation of paralogous transcripts is a potential mechanism of genetic compensation.
About The Cover
ONLINE COVER Break It Up. CD40 receptor binding to CD40 ligand (CD40L) allows B cells (green) to interact with T cells (orange). These interactions lead to high affinity adaptive immune responses that are beneficial for fighting pathogens but detrimental when directed against self targets, such as in autoimmunity. To overcome thrombotic side effects observed with previous antibody-based CD40 therapies, Karnell et al. designed a nonantibody CD40L-targeting molecule that disrupts T cell-B cell collaboration. The molecule inhibited activation of human B cells in vitro, diminished vaccine responses in healthy adults, and lowered disease scores when given to patients with rheumatoid arthritis. [CREDIT: DENNIS KUNKEL MICROSCOPY/SCIENCE SOURCE]